APA (7th ed.) Citation

Papamichael, K., Chachu, K. A., Vajravelu, R. K., Vaughn, B. P., Ni, J., Osterman, M. T., & Cheifetz, A. S. (2017). Improved Long-term Outcomes of Patients With Inflammatory Bowel Disease Receiving Proactive Compared With Reactive Monitoring of Serum Concentrations of Infliximab. Clinical gastroenterology and hepatology, 15(10), 1580-1588.e3. https://doi.org/10.1016/j.cgh.2017.03.031

Chicago Style (17th ed.) Citation

Papamichael, Konstantinos, Karen A. Chachu, Ravy K. Vajravelu, Byron P. Vaughn, Josephine Ni, Mark T. Osterman, and Adam S. Cheifetz. "Improved Long-term Outcomes of Patients With Inflammatory Bowel Disease Receiving Proactive Compared With Reactive Monitoring of Serum Concentrations of Infliximab." Clinical Gastroenterology and Hepatology 15, no. 10 (2017): 1580-1588.e3. https://doi.org/10.1016/j.cgh.2017.03.031.

MLA (9th ed.) Citation

Papamichael, Konstantinos, et al. "Improved Long-term Outcomes of Patients With Inflammatory Bowel Disease Receiving Proactive Compared With Reactive Monitoring of Serum Concentrations of Infliximab." Clinical Gastroenterology and Hepatology, vol. 15, no. 10, 2017, pp. 1580-1588.e3, https://doi.org/10.1016/j.cgh.2017.03.031.